A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
The two companies have inked a deal allowing Yatiri to identify biomarkers that could improve FHD-286's efficacy in advanced AML and MDS patients.
A major study led by the University of Hertfordshire has shown how linking care home data with NHS and social care records can improve residents' lives, strengthen policy decision-making and ensure ...
Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International ...
Building closer relationships with facility staff and health care partners of nursings homes, such as hospital providers and pharmacies, is going to be ...
Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.
Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...
Recently, I had the opportunity to tour two Tennessee whiskey distilleries that I had been wanting to visit for some time, Jack Daniel’s in Lynchburg, TN and Nearest Green just down the road in ...
Geron Corporation (NASDAQ:GERN) is one of the best low priced pharma stocks to buy now. Earlier on May 28, Geron Corporation presented new data on RYTELO (imetelstat) at the 2025 American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results